Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 9/2019

17.05.2019 | Commentary

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France

verfasst von: Damien Botsen, Elise Lepoix, Camille Mazza, Mathilde Brasseur, Anne Grange, Florian Slimano, Olivier Bouché

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

This study was undertaken to assess the previously unevaluated safety and feasibility of oxaliplatin-desensitization procedure add a French ambulatory cancer unit, which is a current topic in oncology. Our findings demonstrated that oxaliplatin-desensitization was safe and feasible in our ambulatory cancer unit. In routine practice, all these procedures are done on an inpatient basis starting at least the day before. Those results could change oncological practices in France and improve patients’ quality of life and lower costs associated with inpatient administration.
Literatur
1.
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRef
2.
Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8(2):106–109CrossRefPubMed
3.
Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89(3):477–481CrossRefPubMedPubMedCentral
4.
Hong DI, Dioun AF (2014) Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2(1):13–19 quiz 20CrossRefPubMed
5.
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580CrossRefPubMed
6.
Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2(1):40–45CrossRefPubMed
7.
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Protocol Development (2010) | CTEP
8.
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez-Cuesta E (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853–861CrossRefPubMed
9.
Le Roy F, Rigault E, Regnault D, Hubert N, Burtin P, Hollebecque A, Malka D, Boige V, Ducreux M (2018) Oxaliplatin desensitization after hypersensitivity reaction: a single-center experience on more than 300 procedures. J Clin Oncol 36(4_suppl):610–610CrossRef
Metadaten
Titel
Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France
verfasst von
Damien Botsen
Elise Lepoix
Camille Mazza
Mathilde Brasseur
Anne Grange
Florian Slimano
Olivier Bouché
Publikationsdatum
17.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04863-5

Weitere Artikel der Ausgabe 9/2019

Supportive Care in Cancer 9/2019 Zur Ausgabe

Original Article

Patient perspectives on adapting meaning-centered psychotherapy in advanced cancer for the Chinese immigrant population

Original Article

Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma

Original Article

Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice

Review Article

Pharmacological evidence of medicinal cannabis in oncology: a systematic review

Original Article

Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence

Original Article

High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen